Katarzyna Fröss-Baron

Hypoalbuminemia, but not derived neutrophil to lymphocyte ratio (dNLR), predicts overall survival in neuroendocrine tumours undergoing peptide receptor radionuclide therapy: A retrospective, cohort study of 557 patients

Papantoniou, Dimitrios; Fröss-Baron, Katarzyna; Garske Roman, Ulrike; Sundin, Anders et al.

Part of Journal of neuroendocrinology, 2025

• DOI for Hypoalbuminemia, but not derived neutrophil to lymphocyte ratio (dNLR), predicts overall survival in neuroendocrine tumours undergoing peptide receptor radionuclide therapy: A retrospective, cohort study of 557 patients
• Download full text (pdf) of Hypoalbuminemia, but not derived neutrophil to lymphocyte ratio (dNLR), predicts overall survival in neuroendocrine tumours undergoing peptide receptor radionuclide therapy: A retrospective, cohort study of 557 patients

Comparison of two prognostic models for the treatment of pancreatic NET with PRRT

Tiensuu Janson, Eva; Fröss-Baron, Katarzyna; Grönberg, Malin; Ziolkowska, B.

Part of Journal of neuroendocrinology, 2025

Tumor growth rate in pancreatic neuroendocrine tumor patients undergoing PRRT with 177Lu-DOTATATE.

Pettersson, Olof; Fröss-Baron, Katarzyna; Crona, Joakim; Sundin, Anders

Part of Endocrine Connections, p. 422-431, 2021

• DOI for Tumor growth rate in pancreatic neuroendocrine tumor patients undergoing PRRT with 177Lu-DOTATATE.
• Download full text (pdf) of Tumor growth rate in pancreatic neuroendocrine tumor patients undergoing PRRT with 177Lu-DOTATATE.

Receptor depletion and recovery in small-intestinal neuroendocrine tumors and normal tissues after administration of a single intravenous dose of octreotide measured by Ga-68-DOTATOC PET/CT

Jahn, Ulrika; Ilan, Ezgi; Velikyan, Irina; Fröss-Baron, Katarzyna et al.

Part of EJNMMI Research, 2021

• DOI for Receptor depletion and recovery in small-intestinal neuroendocrine tumors and normal tissues after administration of a single intravenous dose of octreotide measured by Ga-68-DOTATOC PET/CT
• Download full text (pdf) of Receptor depletion and recovery in small-intestinal neuroendocrine tumors and normal tissues after administration of a single intravenous dose of octreotide measured by Ga-68-DOTATOC PET/CT

177Lu-DOTATATE Therapy of Advanced Pancreatic Neuroendocrine Tumors Heavily Pretreated With Chemotherapy: Analysis of Outcome, Safety and Their Determinants

Fröss-Baron, Katarzyna; Garske, Ulrike; Welin, Staffan; Granberg, Dan et al.

Part of Neuroendocrinology, p. 330-343, 2021

• DOI for 177Lu-DOTATATE Therapy of Advanced Pancreatic Neuroendocrine Tumors Heavily Pretreated With Chemotherapy: Analysis of Outcome, Safety and Their Determinants
• Download full text (pdf) of 177Lu-DOTATATE Therapy of Advanced Pancreatic Neuroendocrine Tumors Heavily Pretreated With Chemotherapy: Analysis of Outcome, Safety and Their Determinants

Hypoalbuminemia, but not derived neutrophil to lymphocyte ratio (dNLR), predicts overall survival in neuroendocrine tumours undergoing peptide receptor radionuclide therapy: A retrospective, cohort study of 557 patients

Papantoniou, Dimitrios; Fröss-Baron, Katarzyna; Garske Roman, Ulrike; Sundin, Anders et al.

Part of Journal of neuroendocrinology, 2025

• DOI for Hypoalbuminemia, but not derived neutrophil to lymphocyte ratio (dNLR), predicts overall survival in neuroendocrine tumours undergoing peptide receptor radionuclide therapy: A retrospective, cohort study of 557 patients
• Download full text (pdf) of Hypoalbuminemia, but not derived neutrophil to lymphocyte ratio (dNLR), predicts overall survival in neuroendocrine tumours undergoing peptide receptor radionuclide therapy: A retrospective, cohort study of 557 patients

Comparison of two prognostic models for the treatment of pancreatic NET with PRRT

Tiensuu Janson, Eva; Fröss-Baron, Katarzyna; Grönberg, Malin; Ziolkowska, B.

Part of Journal of neuroendocrinology, 2025

Tumor growth rate in pancreatic neuroendocrine tumor patients undergoing PRRT with 177Lu-DOTATATE.

Pettersson, Olof; Fröss-Baron, Katarzyna; Crona, Joakim; Sundin, Anders

Part of Endocrine Connections, p. 422-431, 2021

• DOI for Tumor growth rate in pancreatic neuroendocrine tumor patients undergoing PRRT with 177Lu-DOTATATE.
• Download full text (pdf) of Tumor growth rate in pancreatic neuroendocrine tumor patients undergoing PRRT with 177Lu-DOTATATE.

Receptor depletion and recovery in small-intestinal neuroendocrine tumors and normal tissues after administration of a single intravenous dose of octreotide measured by Ga-68-DOTATOC PET/CT

Jahn, Ulrika; Ilan, Ezgi; Velikyan, Irina; Fröss-Baron, Katarzyna et al.

Part of EJNMMI Research, 2021

• DOI for Receptor depletion and recovery in small-intestinal neuroendocrine tumors and normal tissues after administration of a single intravenous dose of octreotide measured by Ga-68-DOTATOC PET/CT
• Download full text (pdf) of Receptor depletion and recovery in small-intestinal neuroendocrine tumors and normal tissues after administration of a single intravenous dose of octreotide measured by Ga-68-DOTATOC PET/CT

177Lu-DOTATATE Therapy of Advanced Pancreatic Neuroendocrine Tumors Heavily Pretreated With Chemotherapy: Analysis of Outcome, Safety and Their Determinants

Fröss-Baron, Katarzyna; Garske, Ulrike; Welin, Staffan; Granberg, Dan et al.

Part of Neuroendocrinology, p. 330-343, 2021

• DOI for 177Lu-DOTATATE Therapy of Advanced Pancreatic Neuroendocrine Tumors Heavily Pretreated With Chemotherapy: Analysis of Outcome, Safety and Their Determinants
• Download full text (pdf) of 177Lu-DOTATATE Therapy of Advanced Pancreatic Neuroendocrine Tumors Heavily Pretreated With Chemotherapy: Analysis of Outcome, Safety and Their Determinants

Tumor Contrast-Enhancement for Monitoring of PRRT Lu-177-DOTATATE in Pancreatic Neuroendocrine Tumor Patients

Pettersson, Olof; Fröss-Baron, Katarzyna; Crona, Joakim; Sundin, Anders

Part of Frontiers in Oncology, 2020

• DOI for Tumor Contrast-Enhancement for Monitoring of PRRT Lu-177-DOTATATE in Pancreatic Neuroendocrine Tumor Patients
• Download full text (pdf) of Tumor Contrast-Enhancement for Monitoring of PRRT Lu-177-DOTATATE in Pancreatic Neuroendocrine Tumor Patients

Kidney dosimetry in 777 patients during ¹⁷⁷Lu-DOTATATE therapy: aspects on extrapolations and measurement time points

Sandström, Mattias; Freedman, Nanette; Fröss-Baron, Katarzyna; Khan, Tanweera et al.

Part of EJNMMI Physics, 2020

• DOI for Kidney dosimetry in 777 patients during ¹⁷⁷Lu-DOTATATE therapy: aspects on extrapolations and measurement time points
• Download full text (pdf) of Kidney dosimetry in 777 patients during ¹⁷⁷Lu-DOTATATE therapy: aspects on extrapolations and measurement time points

In vivo instability of ¹⁷⁷Lu-DOTATATE during peptide receptor radionuclide therapy

Lubberink, Mark; Wilking, Helena; Öst, Amalia; Ilan, Ezgi et al.

Part of Journal of Nuclear Medicine, p. 1337-1340, 2020

• DOI for In vivo instability of ¹⁷⁷Lu-DOTATATE during peptide receptor radionuclide therapy

Favorable Outcome in Patients with Pheochromocytoma and Paraganglioma Treated with ¹⁷⁷Lu-DOTATATE.

Vyakaranam, Achyut Ram; Crona, Joakim; Norlén, Olov; Granberg, Dan et al.

Part of Cancers, 2019

• DOI for Favorable Outcome in Patients with Pheochromocytoma and Paraganglioma Treated with ¹⁷⁷Lu-DOTATATE.
• Download full text (pdf) of Favorable Outcome in Patients with Pheochromocytoma and Paraganglioma Treated with ¹⁷⁷Lu-DOTATATE.

In-vivo stability of ¹⁷⁷Lu-DOTATATE during peptide receptor radionuclide therapy

Wilking, H.; Ilan, Ezgi; Sandström, Mattias; Andersson, C. et al.

Part of European Journal of Nuclear Medicine and Molecular Imaging, 2018

• DOI for In-vivo stability of ¹⁷⁷Lu-DOTATATE during peptide receptor radionuclide therapy

Absorbed doses based on a single measurement point versus three measurement points in 600 patients with neuroendocrine tumours receiving ¹⁷⁷Lu-DOTATATE therapy

Sandström, Mattias; Fröss-Baron, Katarzyna; Khan, Tanweera Shaheena; Granberg, Dan et al.

Part of European Journal of Nuclear Medicine and Molecular Imaging, 2018

• DOI for Absorbed doses based on a single measurement point versus three measurement points in 600 patients with neuroendocrine tumours receiving ¹⁷⁷Lu-DOTATATE therapy

177Lu-DOTATATE Peptide Receptor Radionuclide Therapy; Gender Differences in Small Intestinal and Pancreatic Neuroendocrine Tumors

Jahn, Ulrika; Ilan, Ezgi; Sandström, Mattias; Garske-Román, Ulrike et al.

Part of European Journal of Nuclear Medicine and Molecular Imaging, 2018

Comparison of Ga-68-DOTATATE and Lu-177-DOTATATE kinetics in neuroendocrine tumors

Ilan, Ezgi; Lubberink, Mark; Sandström, Mattias; Jahn, Ulrika et al.

Part of European Journal of Nuclear Medicine and Molecular Imaging, 2018

Prospective observational study of 177Lu-DOTA-octreotate therapy in 200 patients with advanced metastasized neuroendocrine tumours (NETs): feasibility and impact of a dosimetry-guided study protocol on outcome and toxicity

Garske, Ulrike; Sandström, Mattias; Fröss-Baron, Katarzyna; Lundin, Lars et al.

Part of European Journal of Nuclear Medicine and Molecular Imaging, p. 970-988, 2018

• DOI for Prospective observational study of 177Lu-DOTA-octreotate therapy in 200 patients with advanced metastasized neuroendocrine tumours (NETs): feasibility and impact of a dosimetry-guided study protocol on outcome and toxicity
• Download full text (pdf) of Prospective observational study of 177Lu-DOTA-octreotate therapy in 200 patients with advanced metastasized neuroendocrine tumours (NETs): feasibility and impact of a dosimetry-guided study protocol on outcome and toxicity

Gender-related differences in absorbed dose to risk organs in patients receiving Lu-177-Octreotate therapy

Sandström, Mattias; Ilan, Ezgi; Fröss-Baron, Katarzyna; Garske, Ulrike et al.

Part of European Journal of Nuclear Medicine and Molecular Imaging, 2017

Favourable outcome after 177Lu-DOTA-octreotate therapy of patients with neuroendocrine of the rectum -an update

Garske-Roman, Ulrike E.; Sandström, Mattias; Johansson, Silvia; Fröss-Baron, Katarzyna et al.

Part of European Journal of Nuclear Medicine and Molecular Imaging, 2014